Adicet Bio(US:ACET) Businesswire·2024-01-04 12:00Core Insights - Adicet Bio, Inc. is advancing its pipeline of allogeneic gamma delta T cell therapies, with a focus on addressing cancer and autoimmune diseases in 2024 [1][2] Program Updates and Expected Milestones for 2024 - The FDA has cleared the IND application for ADI-001 in lupus nephritis, with plans to initiate a Phase 1 clinical trial in Q2 2024 and provide a clinical update in the second half of 2024 [3][4] - The ongoing Phase 1 GLEAN study will focus on MCL patients, where an 80% complete response (CR) rate and a 60% 6-month CR rate were reported in June 2023 [4] - ADI-270, targeting renal cell carcinoma, is on track to file an IND application in Q2 2024 following positive feedback from the FDA [5][6] Financial Outlook - The company expects to have sufficient cash and cash equivalents to fund operations into the second half of 2025 [7]